PET tau imaging in BLSA and GESTALT as an Early Marker of Alzheimer's Disease

使用Tau放射性配体AV-1451的PET成像于2016年引入BLSA研究。结合PET淀粉样蛋白成像和MRI测量，这些研究将提供阿尔茨海默病临床前阶段的信息。迄今为止，超过115名BLSA参与者至少进行了一次PET Tau扫描，其中一半以上进行了2次或更多次扫描。过去的出版物已经显示了更高的内嗅tau水平和更严重的记忆丧失之间的关联，以及tau负担和人格特征之间的关联。 除了PET生物标志物的研究，我们正在研究AD病理学和神经退行性变的血浆生物标志物，这些生物标志物来自接受过PET淀粉样蛋白和tau蛋白研究的个体样本。 这些测定已在我们的合作者约翰霍普金斯大学的Abhay Moghekar博士和哥德堡大学的Zetterberg、Blennow和Ashton博士的实验室中进行。正在进行的分析正在使用体素分析来检查这些AD生物标志物与PET Tau结合（和PET淀粉样蛋白）的空间分布之间的关系，最近的结果在阿尔茨海默氏病协会国际会议（Bilgel et al. 2023年）。

PET imaging with the Tau radioligand AV-1451 was introduced into the BLSA study in 2016. In combination with PET amyloid imaging and MRI measures, these studies will provide information on the preclinical stages of Alzheimer's Disease. To date more than 115 BLSA participants had at least one PET Tau scan, and of these, more than half had 2 or more scans. Past publications have shown associations between greater entorhinal tau levels and steeper memory loss, as well as associations between tau burden and personality characteristics. In addition to the study of PET biomarkers, we are investigating plasma biomarkers of AD pathology and neurodegeneration in the sample of individuals who have undergone PET amyloid and tau studies. These assays have been performed in the laboratories of our collaborators, Dr. Abhay Moghekar at Johns Hopkins, and Drs. Zetterberg, Blennow and Ashton at Gothenburg University. Ongoing analyses are examining the relation between these AD biomarkers and the spatial distribution of PET Tau binding (and PET amyloid) using voxel wise analysis, with recent results presented at the Alzheimer's Association International Conference (Bilgel et al., 2023).